Oncolytics jumps on Phase III tumor effect data for Reolysin
This article was originally published in Scrip
Oncolytics Biotech continues to provide incremental updates on its Phase III clinical trial in head and neck cancer for Reolysin, the Canadian company's proprietary formulation of the human reovirus, with topline data for one of the double-blind, randomized trial's endpoints: the percentage change in tumors between pre-treatment and post-first treatment scans.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.